VINCENT TAM to Aminoglycosides
This is a "connection" page, showing publications VINCENT TAM has written about Aminoglycosides.
Connection Strength
2.183
-
Outcomes of empiric aminoglycoside monotherapy for Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis. 2019 Apr; 93(4):346-348.
Score: 0.610
-
Kidney injury associated with telavancin dosing regimen in an animal model. Antimicrob Agents Chemother. 2015 May; 59(5):2930-3.
Score: 0.472
-
Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development. Antimicrob Agents Chemother. 2008 Nov; 52(11):3987-93.
Score: 0.301
-
Zileuton ameliorates aminoglycoside and polymyxin-associated acute kidney injury in an animal model. J Antimicrob Chemother. 2023 10 03; 78(10):2435-2441.
Score: 0.214
-
Characterization of Amikacin Drug Exposure and Nephrotoxicity in an Animal Model. Antimicrob Agents Chemother. 2020 08 20; 64(9).
Score: 0.173
-
Once-daily aminoglycosides in the treatment of gram-positive endocarditis. Ann Pharmacother. 1999 May; 33(5):600-6.
Score: 0.158
-
Efficacy of Telavancin Alone and in Combination with Ampicillin in a Rat Model of Enterococcus faecalis Endocarditis. Antimicrob Agents Chemother. 2017 06; 61(6).
Score: 0.138
-
Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother. 2010 Jun; 65(6):1119-25.
Score: 0.084
-
The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections. Intensive Care Med. 2017 Jul; 43(7):1021-1032.
Score: 0.034